High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KABUT Tomáš WEINBERGEROVÁ Barbora FOLBER František LENGEROVÁ Martina MAYER Jiří

Year of publication 2023
Type Article in Periodical
Magazine / Source Bone Marrow Transplantation
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.nature.com/articles/s41409-023-02081-6
Doi http://dx.doi.org/10.1038/s41409-023-02081-6
Keywords CMV infection; high-dose aciclovir
Attached files
Description There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our center. A clinically significant CMV infection (cs-CMVi) was observed in 56 (31%) cases with a median time of 49 (range 25–147) days after HSCT. A significantly higher CMV infection rate was observed in seropositive recipients with a seronegative donor (74%) compared to seropositive recipients with a seropositive donor, and seronegative recipients with seropositive and seronegative donors (24%, 18%, 7% respectively; p?<?0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir’s adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.